{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:51:53Z","timestamp":1775832713667,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical and Health Science Foundation of Zhejiang Province","award":["2023KY1281"],"award-info":[{"award-number":["2023KY1281"]}]},{"name":"Science and Technology Plan Project of Jinhua Science and Technology Bureau","award":["2023-3-110"],"award-info":[{"award-number":["2023-3-110"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12314-x","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T09:45:30Z","timestamp":1754387130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Construction and validation of a lysine beta hydroxybutyrylation related molecular model for predicting biochemical recurrence of prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Desheng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"12314_CR1","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha, M. et al. Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules 27, 5730 (2022).","journal-title":"Molecules"},{"key":"12314_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41585-020-0287-y","volume":"17","author":"AJ Costello","year":"2020","unstructured":"Costello, A. J. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nat. Rev. Urol. 17, 177\u2013188 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"12314_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario, U. G. et al. Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw. Open 6, e2332900 (2023).","journal-title":"JAMA Netw. Open"},{"key":"12314_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/cells9051073","volume":"9","author":"R Montironi","year":"2020","unstructured":"Montironi, R. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells 9, 1073 (2020).","journal-title":"Cells"},{"issue":"Suppl 1","key":"12314_CR5","first-page":"S86","volume":"82","author":"K Mizuno","year":"2022","unstructured":"Mizuno, K. & Beltran, H. Future directions for precision oncology in prostate cancer. Prostate 82(Suppl 1), S86-s96 (2022).","journal-title":"Prostate"},{"key":"12314_CR6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402741121","volume":"121","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics. Proc. Natl. Acad. Sci. U S A 121, e2402741121 (2024).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"12314_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","volume":"41","author":"L de Wet","year":"2022","unstructured":"de Wet, L. et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene 41, 1190\u20131202 (2022).","journal-title":"Oncogene"},{"key":"12314_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2020.09.014","volume":"54","author":"C Diskin","year":"2021","unstructured":"Diskin, C., Ryan, T. A. J. & O\u2019Neill, L. A. J. Modification of proteins by metabolites in immunity. Immunity 54, 19\u201331 (2021).","journal-title":"Immunity"},{"key":"12314_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.molcel.2016.03.036","volume":"62","author":"Z Xie","year":"2016","unstructured":"Xie, Z. et al. Metabolic regulation of gene expression by histone lysine \u03b2-hydroxybutyrylation. Mol. Cell 62, 194\u2013206 (2016).","journal-title":"Mol. Cell"},{"key":"12314_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12943-024-02199-1","volume":"23","author":"Y Lao","year":"2024","unstructured":"Lao, Y. et al. Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma. Mol. Cancer 23, 283 (2024).","journal-title":"Mol. Cancer"},{"key":"12314_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-021-00464-z","volume":"6","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. MTA2 triggered R-loop trans-regulates BDH1-mediated \u03b2-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells. Signal Transduct. Target Ther. 6, 135 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"12314_CR12","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1002\/mco2.449","volume":"4","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. BDH1-mediated LRRC31 regulation dependent on histone lysine \u03b2-hydroxybutyrylation to promote lung adenocarcinoma progression. MedComm 4, e449 (2023).","journal-title":"MedComm"},{"key":"12314_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217808","volume":"625","author":"H Jiang","year":"2025","unstructured":"Jiang, H. et al. Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B \u03b2-hydroxybutyrylation. Cancer Lett. 625, 217808 (2025).","journal-title":"Cancer Lett."},{"key":"12314_CR14","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.2147\/IJGM.S321319","volume":"14","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. & Fu, Y. Comprehensive analysis and identification of an immune-related gene signature with prognostic value for prostate cancer. Int. J. Gen. Med. 14, 2931\u20132942 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"12314_CR15","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.2147\/IJGM.S325347","volume":"14","author":"X Meng","year":"2021","unstructured":"Meng, X., Yuan, H., Li, W., Xiao, W. & Zhang, X. Biomarker screening and prognostic significance analysis for renal cell carcinoma. Int. J. Gen. Med. 14, 5255\u20135267 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"12314_CR16","doi-asserted-by":"publisher","first-page":"eabe2771","DOI":"10.1126\/sciadv.abe2771","volume":"7","author":"H Huang","year":"2021","unstructured":"Huang, H. et al. The regulatory enzymes and protein substrates for the lysine \u03b2-hydroxybutyrylation pathway. Sci. Adv. 7, eabe2771 (2021).","journal-title":"Sci. Adv."},{"key":"12314_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ijc.30069","volume":"139","author":"A Mock","year":"2016","unstructured":"Mock, A. et al. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int. J. Cancer. 139, 424\u2013432 (2016).","journal-title":"Int. J. Cancer."},{"key":"12314_CR18","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672-d677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"12314_CR19","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"12314_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"12314_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.21037\/atm-21-1986","volume":"9","author":"L Cheng","year":"2021","unstructured":"Cheng, L. et al. Identification of an IFN-\u03b2-associated gene signature for the prediction of overall survival among glioblastoma patients. Ann. Transl. Med. 9, 925 (2021).","journal-title":"Ann. Transl. Med."},{"key":"12314_CR22","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad Sci. U. S. A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad Sci. U. S. A."},{"key":"12314_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"12314_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/jcp.29898","volume":"236","author":"ZB Ke","year":"2021","unstructured":"Ke, Z. B. et al. Identification of novel genes in testicular cancer microenvironment based on ESTIMATE algorithm-derived immune scores. J. Cell Physiol. 236, 706\u2013713 (2021).","journal-title":"J. Cell Physiol."},{"key":"12314_CR25","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.18632\/aging.102397","volume":"11","author":"YH Chen","year":"2019","unstructured":"Chen, Y. H. et al. Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis. Aging 11, 9478\u20139491 (2019).","journal-title":"Aging"},{"key":"12314_CR26","doi-asserted-by":"publisher","first-page":"9173","DOI":"10.3390\/ijms24119173","volume":"24","author":"Y Wang","year":"2023","unstructured":"Wang, Y. & Tong, M. Protein posttranslational modification in stemness remodeling and its emerging role as a novel therapeutic target in gastrointestinal cancers. Int. J. Mol. Sci. 24, 9173 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"12314_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","volume":"37","author":"JC Newman","year":"2017","unstructured":"Newman, J. C. & Verdin, E. \u03b2-Hydroxybutyrate: A signaling metabolite. Annu. Rev. Nutr. 37, 51\u201376 (2017).","journal-title":"Annu. Rev. Nutr."},{"key":"12314_CR28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s42255-024-01093-w","volume":"6","author":"J Qin","year":"2024","unstructured":"Qin, J. et al. Ketogenic diet reshapes cancer metabolism through lysine \u03b2-hydroxybutyrylation. Nat. Metab. 6, 1505\u20131528 (2024).","journal-title":"Nat. Metab."},{"key":"12314_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105711","volume":"146","author":"ZB Ke","year":"2022","unstructured":"Ke, Z. B. et al. A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients. Comput. Biol. Med. 146, 105711 (2022).","journal-title":"Comput. Biol. Med."},{"key":"12314_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2023.110691","volume":"115","author":"JY Chen","year":"2023","unstructured":"Chen, J. Y. et al. A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer. Genomics 115, 110691 (2023).","journal-title":"Genomics"},{"key":"12314_CR31","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.21037\/tcr-24-724","volume":"13","author":"H Zheng","year":"2024","unstructured":"Zheng, H., Jiang, W., Zhu, S. & Chen, X. Prognostic significance of B cell senescence-associated genes as risk markers in prostate adenocarcinoma. Transl. Cancer Res. 13, 5771\u20135783 (2024).","journal-title":"Transl. Cancer Res."},{"key":"12314_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-025-06457-8","volume":"23","author":"R Zhuang","year":"2025","unstructured":"Zhuang, R. et al. An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer. J. Transl. Med. 23, 480 (2025).","journal-title":"J. Transl. Med."},{"key":"12314_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12935-024-03305-5","volume":"24","author":"Z Gao","year":"2024","unstructured":"Gao, Z. et al. Comprehensive analyses of the cancer-associated fibroblast subtypes and their score system for prediction of outcomes and immunosuppressive microenvironment in prostate cancer. Cancer Cell Int. 24, 127 (2024).","journal-title":"Cancer Cell Int."},{"key":"12314_CR34","doi-asserted-by":"publisher","first-page":"2399363","DOI":"10.1080\/15384047.2024.2399363","volume":"25","author":"B Zhao","year":"2024","unstructured":"Zhao, B. et al. CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1. Cancer Biol. Ther. 25, 2399363 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"12314_CR35","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41598-025-86950-8","volume":"15","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC. Sci. Rep. 15, 4025 (2025).","journal-title":"Sci. Rep."},{"key":"12314_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.12998\/wjcc.v12.i1.32","volume":"12","author":"Z Song","year":"2024","unstructured":"Song, Z., Zhou, Q., Zhang, J. L., Ouyang, J. & Zhang, Z. Y. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J. Clin. Cases 12, 32\u201341 (2024).","journal-title":"World J. Clin. Cases"},{"key":"12314_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.899384","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Ma, S., Hao, X., Wang, Z. & Sun, Z. Methylation status of TK1 correlated with immune infiltrates in prostate cancer. Front. Genet. 13, 899384 (2022).","journal-title":"Front. Genet."},{"key":"12314_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/pros.24335","volume":"82","author":"PO Lundgren","year":"2022","unstructured":"Lundgren, P. O. et al. Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer. Prostate 82, 911\u2013916 (2022).","journal-title":"Prostate"},{"key":"12314_CR39","first-page":"2211","volume":"9","author":"X Fu","year":"2016","unstructured":"Fu, X. et al. Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. Onco Targets Ther. 9, 2211\u20132220 (2016).","journal-title":"Onco Targets Ther."},{"key":"12314_CR40","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2174\/1871520620666200101141934","volume":"20","author":"JH Tian","year":"2020","unstructured":"Tian, J. H. et al. BUB1B promotes proliferation of prostate cancer via transcriptional regulation of MELK. Anticancer Agents Med. Chem. 20, 1140\u20131146 (2020).","journal-title":"Anticancer Agents Med. Chem."},{"key":"12314_CR41","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.7150\/thno.56604","volume":"11","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics 11, 5794\u20135812 (2021).","journal-title":"Theranostics"},{"key":"12314_CR42","doi-asserted-by":"publisher","first-page":"15594","DOI":"10.18632\/oncotarget.3709","volume":"6","author":"JD Brown-Clay","year":"2015","unstructured":"Brown-Clay, J. D. et al. PBK\/TOPK enhances aggressive phenotype in prostate cancer via \u03b2-catenin-TCF\/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget 6, 15594\u201315609 (2015).","journal-title":"Oncotarget"},{"key":"12314_CR43","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41374-020-00510-4","volume":"101","author":"W Lai","year":"2021","unstructured":"Lai, W. et al. GTSE1 promotes prostate cancer cell proliferation via the SP1\/FOXM1 signaling pathway. Lab. Investig. 101, 554\u2013563 (2021).","journal-title":"Lab. Investig."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12314-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:53:15Z","timestamp":1757343195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12314-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12314"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12314-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Affiliated Jinhua Hospital, Zhejiang University School of Medicine and all patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave final approval of the version to be published, agreed to the submitted journal, and agreed to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"28528"}}